Loading
A phase 1/2 trial of IDP-121 in multiple myeloma, diffuse large B-cell lymphoma, non-Hodgkin lymphoma and chronic lymphocytic leukaemia, run by IDP Discovery Pharma S.L., now recruiting.
A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies is a phase 1/2 interventional study registered as NCT05908409 by IDP Discovery Pharma S.L., with 37 participants planned, started 2023-06-05 and due to reach its primary completion in 2025-12-22. Interventions recorded: IDP-121.
Shares Multiple myeloma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Chronic lymphocytic leukaemia, Multiple myeloma, Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Multiple myeloma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Chronic lymphocytic leukaemia, Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Chronic lymphocytic leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.